Switching from dabigatran to apixaban may be an effective strategy to resolve dabigatran-induced esophagitis without increasing the risk of systemic embolism.
May relieve dabigatran esophagitis symptoms upon apixaban switch; leaves open confirmation of safety and efficacy in larger cohorts.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nagaishi et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: